|
Jan 16
|
Crispr Wins Its Second Gene-Editing Approval In Another Boost To Vertex Stock
|
|
Jan 16
|
UPDATE 2-US FDA approves Vertex/CRISPR gene therapy for an inherited blood disorder
|
|
Jan 16
|
Vertex Announces US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia
|
|
Jan 15
|
Down 88%, Could Editas Medicine Be a Good Investment Now?
|
|
Jan 14
|
What Does It Mean for Investors if CRISPR Therapeutics Gets Bought Out in 2024?
|
|
Jan 14
|
My 3 Highest-Conviction Growth Stocks to Buy in 2024
|
|
Jan 14
|
3 Growth Stocks to Buy That Could Be Massive Long-Term Winners
|
|
Jan 13
|
3 Unstoppable Stocks to Buy in 2024
|
|
Jan 10
|
2 Red Flags for Bluebird Bio Stock
|
|
Jan 10
|
These 3 Stocks Have Beaten the S&P Average Return for Years and Are Likely to Continue That Trend
|